Neurodevelopmental outcomes in children exposed prenatally to levetiracetam

Bshra A. Alsfouk

Abstract

Some old antiseizure medications (ASMs) pose teratogenic risks, including major congenital malformations and neurodevelopmental delay. Therefore, the use of new ASMs in pregnancy is increasing, particularly lamotrigine and levetiracetam. This is likely due to evidence of low risk of anatomical teratogenicity for both lamotrigine and levetiracetam. Regarding neurodevelopmental effects, lamotrigine is the most frequently investigated new ASM with information available for children up to 14 years of age. However, fewer data are available for the effects of levetiracetam on cognitive and behavioral development, with smaller cohorts and shorter follow-up. The aim of the present review was to explicate neurodevelopmental outcomes in children exposed prenatally to levetiracetam to support clinical decision-making. The available data do not indicate an increased risk of abnormal neurodevelopmental outcomes in children exposed prenatally to levetiracetam. Findings demonstrated comparable outcomes for levetiracetam versus controls and favorable outcomes for levetiracetam versus valproate on global and specific cognitive abilities, and behavioral problems. In addition, the available evidence shows no significant dose–effect association for levetiracetam on neurodevelopmental outcomes. However, this evidence cannot be determined definitively due to the limited numbers of exposures with relatively short follow-up. Therefore, further research is required.

Plain Language Summary

Antiseizure medications (ASMs) are medicines that inhibit the occurrence of seizures. Levetiracetam is a new ASM. Some old ASMs are linked with an increased risk of physical birth abnormalities and adverse effects on the child's brain development. Therefore, the use of new ASMs in pregnancy is increasing, especially lamotrigine and levetiracetam. This is likely due to evidence of low risk of birth abnormalities for both lamotrigine and levetiracetam. Regarding effects on development of the brain, lamotrigine is the most frequently examined new ASM with information available for children up to 14 years of age. However, fewer data are available for the effects of levetiracetam on cognitive and behavioral development. Also, levetiracetam studies were smaller and shorter compared with studies investigating lamotrigine effects. The aim of this article was to review the child's brain development effects after exposure to levetiracetam during pregnancy. The available data do not suggest an increased risk of the child having learning or thinking difficulties. Findings demonstrated comparable outcomes for levetiracetam versus controls (i.e. children unexposed to levetiracetam), and favorable outcomes for levetiracetam versus valproate. In addition, the available evidence shows no link between the higher dose of levetiracetam and an increased risk of adverse effects on the child's brain development. However, this evidence cannot be determined definitively due to the limited numbers of children exposed to levetiracetam with relatively short duration of follow-up. Therefore, further research is required.

Keywords: antiepileptic drug, antiseizure medication, child development, epilepsy, in utero exposure, pregnancy, teratogenicity

Received: 20 August 2021; revised manuscript accepted: 2 March 2022.
**Introduction**

Some old antiseizure medications (ASMs) pose teratogenic risks, including major congenital malformations and neurodevelopmental delay.\(^1\)\(^{–}\)\(^3\) Therefore, the use of new ASMs, particularly lamotrigine and levetiracetam, in pregnancy and in women of childbearing age with epilepsy is increasing. In the recent Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study,\(^1\) lamotrigine and levetiracetam were the most frequently prescribed ASMs in monotherapy and also in dual therapy. Likewise, they were the most commonly prescribed ASMs as first-line treatment in women of childbearing potential with epilepsy in a large and recent cohort study.\(^5\) This is likely due to evidence of low risk for major congenital malformations for both lamotrigine and levetiracetam; therefore, they are safer for use during pregnancy than other ASMs. Indeed, findings have consistently demonstrated that *in utero* exposure to lamotrigine or levetiracetam is not associated with increased risk of anatomical teratogenicity.\(^1\)\(^,\)\(^6\)\(^–\)\(^10\)

Regarding neurodevelopmental effects, lamotrigine is the most frequently investigated new ASM, with information available for children up to 14 years of age. Studies have consistently indicated no negative effects on global or specific cognitive outcomes in children exposed prenatally to lamotrigine,\(^3\)\(^,\)\(^11\)\(^–\)\(^15\) but data on autism spectrum disorders are less completely consistent.\(^15\)\(^–\)\(^19\) However, fewer data are available for *in utero* levetiracetam exposure on the child’s cognitive and behavioral development, with smaller cohorts and shorter follow-up. Additional studies on early and later cognition are clearly needed.\(^20\)

There is only one review focusing on new ASMs and neurodevelopment.\(^21\) To date, there has been no review focusing on levetiracetam, which is increasingly used in pregnancy. The aim of the present review was to explicate neurodevelopmental outcomes on children exposed prenatally to levetiracetam to support clinical decision-making.

This work presents a comprehensive general review of all available publications on child neurodevelopment following *in utero* exposure to levetiracetam. Original research, and systematic reviews and meta-analyses investigating cognitive and behavioral outcomes of levetiracetam are reviewed. Two databases were searched: MEDLINE and Web of Science. Search terms related to prenatal exposure, levetiracetam, and child neurodevelopmental outcomes were used. In this article, the word ‘significant’ is employed for the findings that were statistically significant (i.e. \(p < 0.05\) or other significance levels). Exposure to levetiracetam was during entire pregnancy in some studies such as Dutch EURAP & Development study.\(^13\)\(^,\)\(^22\) Other studies included women at different minimum gestational ages such as 20 weeks in MONEAD Study\(^23\) or 30 days before the end of pregnancy in a population-based study by Blotière* et al.*\(^15\)

Eighteen publications were reviewed and included in this work. Table 1 summarizes characteristics and findings of all included studies investigating cognitive and behavioral outcomes in children exposed prenatally to levetiracetam. This narrative summary of the publications divided into levetiracetam *versus* controls, levetiracetam *versus* valproate, and levetiracetam *versus* other ASMs. Each one is analyzed with respect to the following: global cognitive ability (e.g. intelligence quotient (IQ)/developmental quotient (DQ)), specific cognitive abilities (e.g. language, performance, attention), and behavioral problems (e.g. autistic traits, attention deficit hyperactivity disorder (ADHD)). In addition, dose-effect and underlying mechanisms of neurodevelopment are discussed. Finally, future research directions are proposed.

**Levetiracetam versus controls**

*Developmental quotient and Intelligence quotient*

A systematic review and meta-analysis\(^11\) demonstrated that exposure to levetiracetam was not associated with a significant increased risk of cognitive developmental delay in comparison with controls, that is, children of women with untreated epilepsy. Likewise, a prospective study by Videman *et al.*\(^26\) observed comparable general quotient scores of Griffiths Mental Developmental Scale (GMDS) assessed at 7 months of age for levetiracetam-exposed group (\(n = 7\)) compared with unexposed group (\(n = 59\)). In addition, the United Kingdom Epilepsy and Pregnancy Register (UKEPR) study\(^30\) evaluated the early neurodevelopmental ability of children aged under 24 months and reported no significant difference in levetiracetam-exposed children (\(n = 51\)) in comparison with children of women without...
Table 1. Summary of studies investigating cognitive and behavioral outcomes in children exposed prenatally to levetiracetam.

| Study Country | Design | Outcome measure | Study sample size | LEV (n) | Child age at assessment | Key finding | Dose effect for LEV | Maternal IQ | Comment |
|---------------|--------|-----------------|-------------------|---------|-------------------------|-------------|---------------------|-------------|---------|
| MONEAD Study Meador et al. | Prospective, observational study Controls = children of women without epilepsy | Language (primary outcome), motor, cognitive, social-emotional, and general adaptive domains by BSID-III | 271 exposed to ASMs 90 controls | 73 (23 exposed to combination LEV + LTG) | 2 years | In the adjusted analysis, no significant difference in LEV-exposed children and children exposed to other ASMs on language score | Significant only for motor domain for LEV monotherapy, but not other domains. | Adjusted in analysis Maternal IQ associated with language domain scores |
| Blotière et al. | Population-based cohort study | Diagnosis of neurodevelopmental disorders as defined by ICD-10 codes F70-F98, and visits to a speech therapist | 9034 exposed | 621 Median 3.7 years, maximum 6 years | No increased risk of poor outcomes measured in LEV-exposed children compared with LTG group (active comparator) | Not investigated for LEV | Not investigated |
| Dutch EURAP & Development study Huber-Mollema et al. | Prospective observational study Examiner-blinded to ASM exposure | FSIQ, verbal IQ, performance IQ, and processing speed index by WISC-III-NL. Attention/executive functioning, language ability, memory and learning, fine motor skills and visuospatial skills by NEPSY-II-NL | 161 exposed | 25 6 or 7 years | LEV-exposed children achieved better scores for all neurocognitive abilities, particularly language, compared to VPA group. When adjusting maternal IQ and drug dose, LEV group achieved on average 13.4 points higher on verbal IQ compared with VPA group. No significant difference between LEV and LTG groups | No significant dose effect for LEV | Adjusted in analysis Maternal IQ associated with child outcomes |
| Dutch EURAP & Development study Huber-Mollema et al. | Prospective observational study | Child behavioral problems using parent-administered CBCL and SEV | 181 exposed | 30 6-7 years and 11 months | 14% of LEV-exposed children had clinically relevant behavioral problems, lower than VPA (32%) and LTG (16%), and comparable to CBZ (14%). LEV-exposed children had a higher proportion of conduct disorders compared with population norms. LEV group had significantly lower social problems, ADHD symptoms and attention problems than those exposed to VPA. LEV-exposed children had significantly less "ADHD" attention deficit, but significantly more anxious behavior when compared with LTG-exposed children. | No significant relationship between dose of LEV during pregnancy and behavioral outcomes | Maternal IQ not included or investigated Maternal education adjusted in analyses and investigated Significant association between maternal education and child IQ | Part of the cohort was assessed in both studies by Huber-Mollema et al. and Huber-Mollema et al. but for different outcomes |

(Continued)
| Study Country | Design | Outcome measure | Study sample size | LEV (n) | Child age at assessment | Key finding | Dose effect for LEV | Maternal IQ | Comment |
|---------------|--------|-----------------|-------------------|---------|------------------------|-------------|---------------------|-------------|---------|
| MoBa Husebye et al. | Prospective, population-based study | Language impairment by parent-reported ASQ and SLAS | 346 exposed 388 mothers with epilepsy 113,674 mothers without epilepsy | 346 | 5 and 8 years | Risk of language impairment and language scores at age 5 and 8 years did not differ significantly between LEV group and children of women without epilepsy | No significant association between LEV concentration and language outcomes | Maternal IQ not adjusted but maternal education adjusted in analysis | Part of the cohort was assessed in three studies by Husebye et al., Husebye et al., and Bjørk et al., but for different outcomes |
| MoBa Husebye et al. | Prospective, population-based study | Language delay using parent-reported ASQ | 335 exposed 104,222 mothers | 35 (16 monotherapy) | 18 and 36 months | Within folate-supplemented group, LEV had lower language delay proportions in most subdomains than VPA, LTG, TPM, and OXC groups, but higher than CBZ group | No significant correlations between LEV concentrations and language score | – | Part of the cohort was assessed in three studies by Husebye et al., Husebye et al., and Bjørk et al., but for different outcomes |
| MoBa Bjørk et al. | Prospective, population-based study | Autistic traits using parent-reported M-CHAT and SCQ | 179 exposed 75,497 mothers | 12 | 18–36 months | No significant difference between risk of autistic traits in LEV group compared with controls | No significant correlation between LEV concentration and autistic traits | – | Part of the cohort was assessed in three studies by Husebye et al., Husebye et al., and Bjørk et al., but for different outcomes |
| Videman et al. | Prospective observational study | Early processing of emotionally and linguistically relevant sounds using MMN | 36 exposed 46 controls | 6 | Two weeks | No significant differences in LEV group compared with controls or other monotherapies | Not investigated | Not adjusted in analysis | Part of the cohort was assessed in three studies by Videman et al., Videman et al., and Videman et al., but for different outcomes |
| Study Country | Design | Outcome measure | Study sample size | LEV (n) | Child age at assessment | Key finding | Dose effect for LEV | Maternal IQ | Comment |
|---------------|--------|-----------------|-------------------|---------|-------------------------|-------------|-------------------|-------------|---------|
| Videman et al. | Prospective observational study | Control = children unexposed to ASMs but not clear whether their mothers had epilepsy or were healthy, or mixed cohort | Neurodevelopmental scores using GMDS and HINE: Visual attention and orienting to faces using eye tracking test | 56 exposed 62 controls | 7 | 7 months | No significant differences between LEV group and controls in developmental scores and eye-tracker indexes | Correlation not investigated. Mean ± SD (range) 1571 ± 838 (1000–3000) | Maternal IQ did not differ between different ASM groups, or between ASM and control groups | Part of the cohort was assessed in three studies by Videman et al.,25 Videman et al.,26 and Videman et al.27 but for different outcomes |
| Videman et al. | Prospective observational study | Controls = children unexposed to ASMs but not clear whether their mothers had epilepsy or were healthy, or mixed cohort | Early neurological status using HNNE and cortical activity using EEG | 56 exposed 67 controls | 7 | 41–42 weeks of conceptional age | Significant differences between ASM-exposed group and controls but no comparison for individual ASMs | Not investigated | No significant differences in maternal IQ between exposed and control groups | Part of the cohort was assessed in three studies by Videman et al.,25 Videman et al.,26 and Videman et al.27 but for different outcomes |
| Richards et al. | Retrospective population-based study | Control = children unexposed to ASMs but not clear whether their mothers had epilepsy or were healthy, or mixed cohort | Developmental delays and behavioral problems using parent-reported PEDS and SDQ | 616 exposed 286,966 controls | 10 | 4 years | One LEV-exposed child was already under specialist care in PEDS evaluation, and one was referred after SDQ evaluation | Not investigated | Not included | LEV group was not statistically analyzed due to small number |
| Bech et al. | Population-based case-cohort study | Controls = mothers received ASMs at any time but not during pregnancy | Diagnosis of learning disabilities [mental retardation, specific neurodevelopmental or emotional/behavioral conditions, and having special educational needs] | 636 exposed 434 controls | 12 | Median age 6.1 years | LEV group had significant increased risk of learning disability compared with controlsb | No dosage calculations made for LEV | Maternal IQ not adjusted in analysis |
| Veroniki et al. | Systematic review and network meta-analysis | Controls = children of women with untreated epilepsy | Cognitive developmental deficit, autism/dyspraxia, and psychomotor developmental deficit | 29 studies including 5100 children | - | - | Exposure to LEV was not associated with significantly increased risks of cognitive developmental deficit, autism/dyspraxia, or psychomotor developmental deficit compared with controls | - | - | (Continued) |
| Study Country | Design | Outcome measure | Study sample size | LEV (n) | Child age at assessment | Key finding | Dose effect for LEV | Maternal IQ | Comment |
|---------------|--------|-----------------|-------------------|---------|------------------------|-------------|-------------------|------------|---------|
| UKEPR Bromley et al. [29] United Kingdom | Cross-sectional observational study | Neuropsychological assessments conducted blinded LEV versus controls versus VPA | Controls = children of women with untreated epilepsy | 130 exposed 55 controls | 5–9 years 6 years mean age for LEV group | LEV group did not differ significantly from controls in any outcomes measured. Better achievement in children exposed to higher doses of LEV compared with those exposed to higher doses of VPA. No significant differences in outcomes at half the median doses of LEV compared with half the median doses of VPA | No significant dose-effect relationship between LEV and poorer outcomes Mean [range] 1725 [200–4000] | Adjusted in analysis Maternal IQ was predictor for FSIQ, verbal abilities, nonverbal abilities, language, memory, and aspects of attention and executive skills | Significant differences in some demographic variables, such as child age at assessment, maternal IQ, educational level, frequency of seizures and preconceptual folic acid supplements across groups Part of the cohort of Shallcross et al. study was reassessed at older ages in Shallcross et al. and Bromley et al. studies |
| UKEPR Shallcross et al. [30] United Kingdom | Prospective controlled observational study | Locomotor, personal and social, hearing and language, eye and hand coordination, and nonverbal performance skills using GMDS subdomains | Language development ability using GMDS subdomains | 97 exposed 131 controls | 3–4.5 years Mean 42 months | LEV group did not differ significantly from controls in developmental and language abilities. LEV group scored significantly higher than VPA group in gross motor skills and comprehension and expressive language abilities | No correlation between dose of LEV and any outcome measure Mean [range] 2,070 [500–5,000] | Adjusted in analysis | Part of the cohort of Shallcross et al. study was reassessed at older ages in Shallcross et al. and Bromley et al. studies |
| UKEPR Shallcross et al. [30] United Kingdom | Prospective controlled observational study | Early cognitive development [DQ] ability using GMDS subdomains | Locomotor, personal and social, hearing and language, eye and hand coordination, and nonverbal performance skills using GMDS subdomains | 95 exposed 97 controls | Under age 24 months | LEV-exposed group did not differ significantly from controls in overall DQ. LEV-exposed group achieved significantly higher overall DQ than VPA group. LEV group achieved significantly higher scores in all specific cognitive skills of DMDS subdomains compared with VPA group. No significant differences in LEV group compared with controls in any specific cognitive abilities | Not investigate for LEV Mean [range] 1700 [250–4000] | Adjusted in linear regression | Small number in VPA group (n = 44) Part of the cohort of Shallcross et al. study was reassessed at older ages in Shallcross et al. and Bromley et al. studies |

(Continued)
| Study Country | Design | Outcome measure | Study sample size | LEV (n) | Child age at assessment | Key finding | Dose effect for LEV | Maternal IQ | Comment |
|---------------|--------|-----------------|-------------------|---------|-------------------------|-------------|---------------------|------------|---------|
| Arkio et al.32 | United States | Cross-sectional observational study |Any neurodevelopmental diagnosis | 62 exposed | 11 | – | No LEV-exposed children had motor development or speech delay compared with 2/24 in LTG, 3/17 in CBZ, and 1/2 in VPA groups | – | – | Pilot study |
| Bromley et al.3 | Systematic review and meta-analysis | LEV versus controls versus VPA | Controls = children of women without epilepsy | 28 cohort studies | One study | – | Nonsignificant mean difference (1.09, 95% CI -2.81 to 4.99, p = 0.58) for LEV compared with controls LEV-exposed group had better global cognitive development compared with VPA with significant mean difference (12.03, 95% CI 6.24 to 17.82, p < 0.0001) | – | – | Only one study included30 |

3Number of exposures to levetiracetam monotherapy.
4Statistically significant (i.e., p value < 0.05 or other significance levels).

ADHD, attention deficit hyperactivity disorder; ASMs, antiseizure medications; ASQ, Ages and Stages Questionnaire; BASC-II, Behavior Assessment System for Children, Second Edition; BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CBCL, Child Behavior Checklist; CBZ, carbamazepine; CELF-IV, Clinical Evaluation of Language Fundamentals–Fourth Edition; CI, confidence interval; DQ, developmental quotient; EEG, electroencephalography; FSIQ, full-Scale Intelligence Quotient; GBP, gabapentin; GMDS, Griffiths Mental Development Scales; HINE, Hammersmith Infant Neurological Examination; HNNE, Hammersmith Neonatal Neurological Examination; ICD-10, International Classification of Diseases, 10th Revision; IQ, intelligence quotient; LEV, levetiracetam; LTG, lamotrigine; M-CHAT, Modified Checklist for Autism in Toddlers; MMN, mismatch negativity; MoBa, Mother and Child Cohort Study; MONED study, Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study; NEPSY-II-NL, Developmental Neuropsychological Assessment; 2nd edition, Netherlands; OXC, oxcarbazepine; PEDS, Parental Evaluation of Development Status; RLDS, Reynell Language Development Scale; SCQ, Social Communication Questionnaire; SD, standard deviation; SDQ, Strengths and Difficulties Questionnaire; SEV, Social-Emotional Questionnaire; SLAS, Speech and Language Assessment Scale; TPM, topiramate; UKEPR, United Kingdom Epilepsy and Pregnancy Register; VPA, valproate; WISC-III-NL, Wechsler Intelligence Scale for Children, Third Edition, Netherlands; WISC-IV, Wechsler Intelligence Scale for Children–Fourth Edition; WPPSI-III, Wechsler Preschool and Primary Scale of Intelligence–Third Edition.
epilepsy ($n=97$) in overall DQ of GMDS (mean 99.9 versus 98.8, respectively, $p=0.62$). The UKEPR follow-up study$^{29}$ investigated full-scale IQ (FSIQ) at age 5–9 years utilizing the Wechsler Intelligence Scale for Children (WISC-IV), or the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III) if the children were 5 years old, in children exposed to levetiracetam ($n=42$) compared with children of mothers with untreated epilepsy ($n=55$). In this study, a comparable FSIQ in levetiracetam-exposed children compared with controls (mean 99.0 versus 99.7, respectively) was observed, and in the adjusted analyses, being exposed to levetiracetam was not associated with poorer outcome on FSIQ ($p=0.47$).

However, a population-based study by Bech et al.$^{28}$ observed an increased risk of learning disability in levetiracetam-exposed children compared with unexposed children. However, the levetiracetam-exposed group was small ($n=12$), and there was no adjustment for important confounding factors in analyses, such as maternal IQ.

**Specific cognitive abilities**

Language abilities and risk of language impairment did not differ significantly between levetiracetam-exposed children at age 5 ($n=17$) and 8 years ($n=6$), and children of mothers without epilepsy in a study by Husebye et al.$^{14}$ Furthermore, the systematic review and meta-analysis$^{11}$ demonstrated that exposure to levetiracetam was not associated with a significant increased risk of psychomotor developmental delay in comparison with controls, i.e. children of women with untreated epilepsy. In addition, Videman et al.$^{26}$ observed no significant difference in sub-quotient scores (locomotor, personal-social, hearing and language, eye and hand coordination, and performance) of GMDS at age 7 months between the levetiracetam group and the unexposed group. However, the levetiracetam group had higher (but not significantly) eye-tracker indexes than controls. The mean ages of children exposed to levetiracetam and control children in the eye-tracker test were comparable but there was a small number of exposures to levetiracetam ($n=7$).

In the UKEPR study,$^{30}$ the levetiracetam-exposed group did not differ significantly from controls at age under 24 months in any specific cognitive abilities of GMDS: locomotor (mean 97.3 versus 95.2, respectively, $p=0.4$), personal and social (mean 98 versus 97.9, respectively, $p=0.99$), hearing and language (mean 100.5 versus 101.2, respectively, $p=0.79$), hand–eye coordination (mean 101.8 versus 97.4, respectively, $p=0.14$), and performance (mean 101.7 versus 101.4, respectively, $p=0.92$). Likewise, the UKEPR follow-up study at age 3–4.5 years$^{11}$ observed no significant differences in any subdomains of GMDS between levetiracetam-exposed children ($n=53$) and children of women without epilepsy ($n=131$): motor scores (mean 110.4 versus 110.9, respectively, $p=0.9$), personal score (mean 116.5 versus 119.9, respectively, $p=0.1$), hand–eye coordination (mean 104.8 versus 103.3, respectively, $p=0.8$), performance score (mean 109.9 versus 110.5, respectively, $p=0.6$), and practical score (mean 113.4 versus 113.9, respectively, $p=0.5$). The study also investigated language development using the Reynell Scales of Infant and Toddler Development (RDLS) at age 3–4.5 years. No significant differences were observed between levetiracetam-exposed children and controls in language comprehension (mean 49.6 versus 52.2, respectively, $p=0.2$). However, levetiracetam-exposed children obtained significantly higher scores in language expression skills compared with controls (mean 52.0 versus 46.6, respectively, $p=0.01$), but after adjusting for confounding variables, the difference was not significant ($p=0.03$, significance level was $\leq 0.007$ after Bonferroni correction).$^{31}$ The UKEPR follow-up study at age 5–9 years$^{29}$ reported comparable outcomes for levetiracetam-exposed children in comparison with children of mothers with untreated epilepsy in verbal abilities (mean 101.0 versus 101.7, respectively), nonverbal abilities (mean 99.6 versus 100.8, respectively), and processing speed (mean 94.7 versus 97.1, respectively), and when outcomes were adjusted for covariates, being exposed to levetiracetam was not associated with poor outcomes in verbal abilities ($p=0.51$), nonverbal abilities ($p=0.72$), or processing speed ($p=0.51$). Bromley et al.$^{29}$ evaluated other specific cognitive abilities using the NEPSY-II (Developmental Neuropsychological Assessment) and the Clinical Evaluation of Language Fundamentals (CELF-IV). The adjusted analyses in this study showed that being exposed to levetiracetam was not associated significantly with poorer outcomes in language, memory, attention or executive functioning.
In the recent MONEAD study, a large number of mothers received levetiracetam as monotherapy (n=70/211, 33.2%) or in combination with lamotrigine (n=25/55, 45%). Language domain score using the Bayley Scales of Infant and Toddler Development (BSID-III) was investigated for children of women with epilepsy (n=292) in comparison with healthy women (n=90) at 2 years of age. There were no significant differences in language domain score (p=0.81) or other domains, including motor (p=0.25), cognitive (p=0.7), social-emotional (p=0.15), and general adaptive (0.86) skills, between children of women with epilepsy and healthy women in the adjusted model. However, there was no subanalysis for levetiracetam monotherapy versus controls.

**Behavioral problems**

Huber-Mollema et al. examined child behavioral problems using the parent-administered Child Behavior Checklist (CBCL) and the Social-Emotional Questionnaire (SEV) at age 6–8 years. The study showed that, compared with population norms, there were no differences in ADHD or anxious behavior. However, levetiracetam-exposed children had a higher proportion of conduct disorders. Bjørk et al. investigated the parental rating of autistic traits using the Modified Checklist for Autism in Toddlers (M-CHAT) and the Social Communication Questionnaire (SCQ) at 18 and 36 months of age, respectively. No significant difference was reported in the risk of autistic traits between children exposed to levetiracetam (n=12) and children of women with no maternal epilepsy at age of 3 years. Likewise, Bromley et al. assessed parent-rated child behavior using the Behavior Assessment System for Children (BASC-II) at age 5–9 years and observed that exposure to levetiracetam was not associated significantly with poorer outcomes in behavioral variable compared with children of mothers with untreated epilepsy.

It should be noted that above studies used parental rating of child behaviors and autistic traits, which may be considered a limitation compared with diagnosis and clinical referral assessments. In addition, parent-administered scales may pose risk of biased rating because parents are not blinded to type of medication exposure.

Consistent with the above research, the systematic review and meta-analysis demonstrated that exposure to levetiracetam was not associated with significantly increased risk of autism/dyspraxia compared with controls of women with epilepsy who did not receive ASMs.

**Levetiracetam versus valproate**

**Developmental quotient and Intelligence quotient**

In the UKPR study, the levetiracetam-exposed group (n=51) achieved significantly higher scores than the valproate group (n=44) under the age of 2 years in overall DQ (mean 99.9 versus 87.9, respectively, p<0.001). Similarly, in the follow-up study, children exposed to levetiracetam had higher unadjusted mean score for FSIQ compared with those exposed to valproate (99 versus 95.5, respectively), as well as the rate of below-average (<85) performance for FSIQ was lower in the levetiracetam group (12%, n=5/42) than the valproate group (19%, n=9/47). Furthermore, children exposed to higher doses of levetiracetam performed better in comparison to children exposed to higher doses of valproate. However, there were no significant differences in outcomes at half the median dose of levetiracetam (750 mg/day) in comparison with half the median dose of valproate (400 mg/day).

A prospective study by Huber-Mollema et al. observed better outcomes in levetiracetam-exposed children compared with the valproate group in verbal abilities (mean 114 versus 100.6, respectively) and processing speed (mean 111.2 versus 107.4, respectively), and comparable outcomes in performance abilities (mean 104.4 versus 105.3, respectively).
in unadjusted analysis. When adjusting for maternal IQ and drug dose, children exposed to levetiracetam were on average 13.4 points higher than valproate-exposed children in verbal abilities (p = 0.002). There were no significant differences in performance abilities or processing speed. The study also investigated other specific cognitive domains, including attention and executive function, language, memory and learning, fine motor skills, and visuospatial skills by NEPSY-II-NL. Levetiracetam-exposed children achieved better scores in all these neurocognitive abilities compared with the valproate group; the differences were significant in the following subdomains: statue and inhibition naming of attention and executive functioning; and comprehension of instruction and vocabulary of language skills. The authors also noticed that children exposed to levetiracetam were associated with more disharmonic profiles (verbal IQ > performance IQ), opposite to that seen in the valproate group. Nevertheless, the sample size was small, and findings need to be confirmed by further research.

In Shallcross et al.\textsuperscript{30} study, the levetiracetam group achieved significantly higher scores than the valproate group under the age of 2 years in locomotor skills (mean 97.3 \textit{versus} 84.6, respectively, \(p < 0.001\)), personal and social skills (mean 98 \textit{versus} 89.8, respectively, \(p = 0.03\)), hearing and language (mean 100.5 \textit{versus} 90.4, respectively, \(p = 0.01\)), hand/eye coordination (mean 101.8 \textit{versus} 88.2, respectively, \(p < 0.001\)), and performance skills (mean 101.7 \textit{versus} 88.8, respectively, \(p < 0.00\)). Likewise, Shallcross et al.\textsuperscript{31} found that levetiracetam-exposed children achieved significantly higher scores (on average 15.8 points) than the valproate group at age 3–4.5 years in gross motor skills (\(p < 0.001\)), 6.4 points higher in comprehension language abilities (\(p < 0.005\)), and 9.5 points higher in expressive language abilities (\(p < 0.001\)). But no significant differences were observed in personal and social skills (\(p = 0.04\); significance level was \(\leq 0.007\) after Bonferroni correction), hand/eye coordination (\(p = 0.5\)), nonverbal performance skills, (\(p = 0.8\)), or practical reasoning (\(p = 0.4\)) at this older age assessment.

Although there was no direct comparison between children exposed to levetiracetam \textit{versus} valproate in the study conducted by Husebye et al.,\textsuperscript{14} the study showed that rate of language impairment for the levetiracetam group was 22% (\(n = 2/9\)) at age 5% and 17% (\(n = 1/6\)) at age 8 years, lower than the rates in the valproate group which were 36% (\(n = 5/14\)) at age 5% and 31% (\(n = 5/16\)) at age 8. Furthermore, mean language scores at age 5 years were higher for levetiracetam than valproate [Ages and Stages Questionnaire (ASQ) scores of 68 \textit{versus} 64, and Speech and Language Assessment Scale (SLAS) scores of 3.7 \textit{versus} 3.1, respectively].

However, Videman et al.\textsuperscript{26} found no significant differences in eye-tracker indexes (visual attention and orienting to faces) between levetiracetam and valproate groups.

\textbf{Behavioral problems}

Huber-Mollema \textit{et al.}\textsuperscript{22} found that the rate of clinically relevant behavior problems was lower in levetiracetam-exposed children (14%) than in the valproate group (32%). Furthermore, after controlling for key covariates, including maternal behavioral problems, the levetiracetam group (\(n = 30\)) had significantly fewer social problems (\(p = 0.028\)), attention problems (\(p = 0.013\)), ADHD symptoms (\(p = 0.03\)), and attention deficit (\(p = 0.022\)) compared with the valproate group (\(n = 26\)).

\textbf{Levetiracetam versus other antiseizure medications}

\textit{Developmental quotient and Intelligence quotient}

Huber-Mollema \textit{et al.}\textsuperscript{13} showed no significant difference in FS IQ between children exposed to levetiracetam (\(n = 25\)) and lamotrigine (\(n = 82\)) at age 6–7 years. In the analysis adjusted for maternal IQ, there were comparable mean FS IQ scores between levetiracetam and lamotrigine groups (109.2 \textit{versus} 109.1, respectively).

Bech \textit{et al.}\textsuperscript{28} investigated the risk of learning disability with each ASM monotherapy, including levetiracetam (\(n = 12\)), carbamazepine (\(n = 35\)), clonazepam (\(n = 43\)), gabapentin (\(n = 29\)), lamotrigine (\(n = 290\)), oxcarbazepine (\(n = 44\)), phenobarbital (\(n = 11\)), topiramate (\(n = 27\)), and valproate (\(n = 55\)), and found that \textit{in utero} exposure to levetiracetam was not associated with a higher risk [odds ratio: 5.45, 95% confidence interval (CI): 0.78–38.02, \(p = 0.087\)] compared with other ASMs.
Specific cognitive abilities

Huber-Mollema et al.\textsuperscript{13} compared neurodevelopmental outcomes in children aged 6–7 years exposed to levetiracetam \((n=25)\) and lamotrigine \((n=82)\) in an adjusted analysis that controlled for maternal IQ and dose. This study showed no significant differences in verbal abilities, performance abilities, and processing speed, as well as attention and executive function, language, memory and learning, fine motor skills or visuospatial skills, except for visuomotor precision subdomain of fine motor skill in which levetiracetam-exposed children obtained significantly lower scores than lamotrigine-exposed children \((p=0.022)\). In the MONEAD study,\textsuperscript{23} the 2-year BSID-III language score for levetiracetam monotherapy \((n=73)\) did not differ significantly \((p=0.175)\) from other ASM monotherapies \(\text{[lamotrigine (n=93), oxcarbazepine (n=13), carbamazepine (n=12), zonisamide (n=11), and topiramate (n=5)]}\). Likewise, no significant differences in eye-tracker indexes \(\text{(visual attention and orienting to faces)}\) were found between levetiracetam compared to carbamazepine, oxcarbazepine, and lamotrigine.\textsuperscript{26}

Behavioral problems

In a large population-based study conducted by Blotière et al.,\textsuperscript{15} the risk of neurodevelopmental disorder was investigated. Also, the risk of communication-related conditions was evaluated by ‘visits to a speech therapist’. The study demonstrated that prenatal exposure to levetiracetam \((n=621)\) was not associated with increased risk of any neurodevelopmental outcomes compared with lamotrigine \((n=1627)\), active comparator. The results stood after sensitivity analysis. However, the children were followed up to a maximum of 6 years age \(\text{(average 3.7 years)}\), which allowed detection only of early diagnoses of neurodevelopmental disorders. There are several strengths to this study by Blotière et al.\textsuperscript{15} it represents the largest study to date that evaluated neurodevelopmental disorders in levetiracetam-exposed children, the use of lamotrigine as active comparator, and outcomes measured by clinical diagnosis/visits to speech therapy rather than parental reporting.

Other studies have been based on parental reporting of child behaviors. Huber-Mollema et al.\textsuperscript{22} demonstrated that 14% of levetiracetam-exposed children had clinically relevant behavioral problems, lower than for lamotrigine \((16\%)\), and comparable to carbamazepine \((14\%)\). In the adjusted analysis, levetiracetam-exposed children \((n=30)\) had significantly less ‘ADHD’ attention deficit \((p=0.026)\), but significantly more anxiety problems \((p=0.042)\) compared with lamotrigine-exposed children \((n=88)\). However, children exposed to levetiracetam or lamotrigine had scores comparable to population norms for parental reports of attention and anxiety behaviors. There were no significant differences in other behavioral outcomes between levetiracetam and lamotrigine. Although there were no direct comparisons or statistical tests performed between children exposed to levetiracetam \(\text{versus other individual ASMs in the study by Husebye et al.,}\textsuperscript{14} the study demonstrated that the rate of language impairment for the levetiracetam group was 22% \((n=2/9)\) at age 5% and 17% \((n=1/6)\) at age 8 years, lower than the rates for other ASMs (carbamazepine: 35% and 43%, lamotrigine: 23% and 22%, topiramate: 50% and 25% at age 5 and 8 years, respectively). Furthermore, mean language scores at age 5 years were higher for levetiracetam \(\text{(ASQ score 68, SLAS score 3.7)}\) than for other ASMs \(\text{(ASQ and SLAS scores for carbamazepine: 56.3 and 3.3, for lamotrigine: 65.3 and 3.4, for topiramate: 64.6 and 3.5, respectively).}\)

Dose effect

All studies found no significant association between dose of levetiracetam,\textsuperscript{13,16,22,29,31} or levetiracetam concentration\textsuperscript{14,24} and poor neurodevelopmental outcomes. Except in the MONEAD study,\textsuperscript{23} higher maximum third-trimester ABLs \(\text{(antiseizure medication blood level)}\) for levetiracetam monotherapy was significantly associated with lower BSID-III scores for the motor domain \((−13.0; 95\% \text{CI}: −22.1 \text{to } −4.0)\). However, other domains, including language \(\text{(primary outcome)}\), cognitive, social-emotional, or general adaptive domains, were not associated with third-trimester ratio of ABL for levetiracetam.

Mechanisms of neurodevelopmental effects of antiseizure medications

Several hypotheses may explain why levetiracetam is not associated with increased risk of abnormal neurodevelopmental effects while some other ASMs, such as valproate, have adverse neurodevelopmental effects. The exact underlying neurobiological mechanisms of behavioral and cognitive effects in children exposed prenatally to other ASMs are uncertain.\textsuperscript{33,34} However, levetiracetam...
is known to have a novel structure and a unique mechanism of action distinct from that of other ASMs. Levetiracetam binds to synaptic vesicle protein SV2A, which modulates vesicle exocytosis and neurotransmitter release.\textsuperscript{35,36}

Likewise, research regarding apoptosis in animal studies may explain the neurodevelopmental differences between children exposed to levetiracetam and other ASMs. ASM-induced neuronal apoptosis in animal studies is a possible mechanism implicated in the development of adverse cognitive effects in humans after fetal exposure to ASMs.\textsuperscript{37,38} Certain ASMs, including valproate, can induce neuronal apoptosis.\textsuperscript{37} Some ASMs do not induce apoptosis in monotherapy but can enhance it when added to another ASM.\textsuperscript{39} Levetiracetam does not induce apoptosis in monotherapy or enhance the apoptosis of other ASMs.\textsuperscript{38} Furthermore, it has been found that ASMs with proapoptotic action can also impair the physiological maturation of synapses in surviving neurons. However, levetiracetam, an ASM with no proapoptotic action, does not disrupt synaptic development.\textsuperscript{40}

**Conclusion**

The available data do not indicate an increased risk of abnormal neurodevelopmental outcomes in children exposed prenatally to levetiracetam. Findings demonstrated comparable outcomes for levetiracetam versus controls and favorable outcomes for levetiracetam versus valproate in global and specific cognitive abilities, and behavioral problems. Furthermore, the available research does not indicate any worse effects of levetiracetam on child neurodevelopment compared with lamotrigine. In addition, the available evidence shows no significant dose-effect association of levetiracetam and adverse neurodevelopmental outcomes. However, as concluded by the Medications and Healthcare products Regulatory Agency,\textsuperscript{41} this evidence cannot be determined definitively due to the limited number of exposures with relatively short follow-up. Therefore, further research is required.

**Future directions**

This review proposes several avenues for future research. The duration of follow-up in studies of levetiracetam was up to age 9 years. This is inadequate to establish long-term effects on cognitive and behavioral development beyond childhood.\textsuperscript{21,34,42,43} An evaluation in their adolescent years of exposed children is required. In addition, evaluation of dose effects is a key principle in neurobehavioral teratology and is important in supporting real-world clinical decision-making. The recent MONEAD study\textsuperscript{23} showed a significant concentration-effect association with motor skills for levetiracetam. However, no other earlier studies found significant dose–response correlations for levetiracetam. Nevertheless, in order to reveal dose effects, adequate sample sizes, utilizing ASM blood levels, are required.\textsuperscript{21} Furthermore, most studies compared levetiracetam to unexposed or valproate and were important to show the relative risks. However, valproate now must be avoided in women of childbearing potential.\textsuperscript{44} Therefore, direct comparisons between levetiracetam and other new ASMs are needed. There is also a need for investigation of other factors that may affect neurodevelopmental outcomes such as parental IQ, socioeconomic status, folate supplementation, child age and gender, gestational age at birth and breastfeeding. Adjustments for potential confounders are also required.\textsuperscript{21,42} Finally, further research is needed for a better understanding of the underlying mechanisms of the neurodevelopmental effects of levetiracetam.

**References**

1. Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. *Cochrane Database Syst Rev* 2016; 11: CD010224.
2. Tomson T and Battino D. Teratogenic effects of antiepileptic drugs. *Lancet Neurol* 2012; 11: 803–813.

3. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. *Cochrane Database Syst Rev* 2014; 10: CD010236.

4. Meador KJ, Pennell PB, May RC, et al. Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy. *Epilepsy Behav* 2018; 84: 10–14.

5. Kim H, Faught E, Thurman DJ, et al. Antiepileptic drug treatment patterns in women of childbearing age with epilepsy. *JAMA Neurol* 2019; 76: 783–790.

6. Veroniki AA, Cogo E, Rios P, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. *BMC Med* 2017; 15: 95.

7. Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. *Lancet Neurol* 2018; 17: 530–538.

8. Vajda FJE, Graham JE, Hitchcock AA, et al. Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. *Seizure* 2019; 65: 6–11.

9. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. *Neurology* 2012; 78: 1692–1699.

10. Cunnington MC, Weil JG, Messenheimer JA, et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. *Neurology* 2011; 76: 1817–1823.

11. Veroniki AA, Rios P, Cogo E, et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. *BMJ Open* 2017; 7: e017248.

12. Cohen MJ, Meador KJ, May R, et al. Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: the NEAD prospective observational study. *Epilepsy Behav* 2019; 92: 154–164.

13. Huber-Mollema Y, van Iterson L, Oort FJ, et al. Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure. *J Neurol* 2020; 267: 1724–1736.

14. Husebye ESN, Gilhus NE, Spigset O, et al. Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero – the Norwegian Mother and Child Cohort Study. *Eur J Neurol* 2020; 27: 667–675.

15. Blotière P-O, Miranda S, Weill A, et al. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. *BMJ Open* 2020; 10: e034829.

16. Björk M, Riedel B, Spigset O, et al. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs in utero. *JAMA Neurology* 2018; 75: 160–168.

17. Veiby G, Daltveit AK, Schjolberg S, et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. *Epilepsia* 2013; 54: 1462–1472.

18. Bromley RL, Mawer GE, Briggs M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. *J Neurol Neurosurg Psychiatry* 2013; 84: 637–643.

19. Richards N, Reith D, Stitely M, et al. Developmental outcomes at age four following maternal antiepileptic drug use. *Epilepsy Behav* 2019; 93: 73–79.

20. Tomson T, Battino D, Bromley R, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. *Epileptic Disord* 2019; 21: 497–517.

21. Knight R, Wittkowski A and Bromley RL. Neurodevelopmental outcomes in children exposed to newer antiseizure medications: a systematic review. *Epilepsia* 2021; 62: 1765–1779.

22. Huber-Mollema Y, Oort FJ, Lindhout D, et al. Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy. *Epilepsia* 2019; 60: 1069–1082.

23. Meador KJ, Cohen MJ, Loring DW, et al. Two-year-old cognitive outcomes in children of pregnant women with epilepsy in the maternal outcomes and neurodevelopmental effects of antiepileptic drugs study. *JAMA Neurol* 2021; 78: 927–936.

24. Husebye ESN, Gilhus NE, Riedel B, et al. Verbal abilities in children of mothers with epilepsy: association to maternal folate status. *Neurology* 2018; 91: e811–e821.
25. Videman M, Stjerna S, Wikström V, et al. Prenatal exposure to antiepileptic drugs and early processing of emotionally relevant sounds. *Epilepsy Behav* 2019; 100: 106503.

26. Videman M, Stjerna S, Roivainen R, et al. Evidence for spared attention to faces in 7-month-old infants after prenatal exposure to antiepileptic drugs. *Epilepsy Behav* 2016; 64: 62–68.

27. Videman M, Tokariev A, Stjerna S, et al. Effects of prenatal antiepileptic drug exposure on newborn brain activity. *Epilepsia* 2016; 57: 252–262.

28. Bech LF, Polcwiartek C, Kragholm K, et al. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. *J Neurol Neurosurg Psychiatry* 2018; 89: 1324–1331.

29. Bromley RL, Calderbank R, Cheyne CP, et al. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. *Neurology* 2016; 87: 1943–1953.

30. Shallcross R, Bromley RL, Irwin B, et al. Child development following in utero exposure: levetiracetam vs sodium valproate. *Neurology* 2016; 87: 1943–1953.

31. Arkilo D, Hanna J, Dickens D, et al. Pregnancy and neurodevelopmental outcomes with in-utero antiepileptic agent exposure. A pilot study. *Eur J Paediatr Neurol* 2015; 19: 37–40.

32. Gedzelman ER and Meador KJ. Neurological and psychiatric sequelae of developmental exposure to antiepileptic drugs. *Front Neurol* 2012; 3: 182.

33. Meador KJ and Loring DW. Developmental effects of antiepileptic drugs and the need for improved regulations. *Neurology* 2016; 86: 297–306.

34. Wright C, Downing J, Mungall D, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. *Front Neurol* 2013; 4: 192.

35. Lyseng-Williamson KA. Spotlight on levetiracetam in epilepsy. *CNS Drugs* 2011; 25: 901–905.

36. Bittigau P, Sifringer M and Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. *Ann NY Acad Sci* 2003; 993: 103–114; discussion 123–124.

37. Manthey D, Asimiadou S, Stefovska V, et al. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. *Exp Neurol* 2005; 193: 497–503.

38. Katz I, Kim J, Gale K, et al. Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain. *J Pharmacol Exp Ther* 2007; 322: 494–500.

39. Forcelli PA, Janssen MJ, Vicini S, et al. Neonatal exposure to antiepileptic drugs disrupts striatal synaptic development. *Ann Neurol* 2012; 72: 363–372.

40. Medications and Healthcare products Regulatory Agency. Antiepileptic drugs: review of safety of use during pregnancy, https://www.gov.uk/government/publications/public-assesment-report-of-antiepileptic-drugs-review-of-safety-of-use-during-pregnancy/antiepileptic-drugs-review-of-safety-of-use-during-pregnancy (accessed 23 July 2021).

41. McCorry D and Bromley R. Does in utero exposure of antiepileptic drugs lead to failure to reach full cognitive potential? *Seizure* 2015; 28: 51–56.

42. Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. *Epilepsia* 2015; 56: 1006–1019.